Skip to main content
SymBio Pharmaceuticals Limited logo

SymBio Pharmaceuticals Limited — Investor Relations & Filings

Ticker · 4582 ISIN · JP3383050006 T Manufacturing
Open in API
Filings indexed 80 across all filing types
Latest filing 2026-04-17 Share Issue/Capital Cha…
Country JP Japan
Listing T 4582

About SymBio Pharmaceuticals Limited

https://www.symbiopharma.com/en/

SymBio Pharmaceuticals Limited is a specialty pharmaceutical company focused on the development and commercialization of new drug candidates. The company's business model involves acquiring development and marketing rights for promising pharmaceuticals from other bio-ventures and pharmaceutical firms to address unmet medical needs. Its core therapeutic areas include oncology, hematology, and rare diseases. A key product in its portfolio is bendamustine hydrochloride (Treakisym), an agent used in the treatment of hematologic cancers such as low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. SymBio aims to deliver innovative treatments to patients by advancing its pipeline of specialized drugs.

Recent filings

Filing Released Lang Actions
訂正臨時報告書
Share Issue/Capital Change Classification · 91% confidence The document is an "臨時報告書" (timely/extraordinary report) filed under the Financial Instruments and Exchange Act, detailing the issuance of new stock subscription rights (stock options) to directors and employees. This constitutes a direct change to the company’s capital via issuance of new equity interests. It is not an earnings announcement, call transcript, or AGM material, but a regulatory filing on share issuance. According to the taxonomy, this falls under "Share Issue/Capital Change" (SHA).
2026-04-17 Japanese
確認書
Regulatory Filings Classification · 82% confidence The document is a short “confirmation letter” (確認書) filed under Japan’s Financial Instruments and Exchange Act, confirming management’s attestation of the year-end securities report (有価証券報告書) contents for the fiscal year. It is not the full annual report itself nor a typical earnings release or dividend notice, but rather a compliance/regulatory submission. It falls into the fallback category for miscellaneous regulatory filings.
2026-03-24 Japanese
有価証券報告書－第21期(2025/01/01－2025/12/31)
Annual Report Classification · 100% confidence The document is a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the Japanese equivalent of a 10-K annual report. It is filed under the Financial Instruments and Exchange Act, covers a full fiscal year (2025-01-01 to 2025-12-31), and contains comprehensive financial statements, management discussion, and corporate information. It is not an announcement or a summary, but the full annual filing. FY 2025
2026-03-24 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act. It serves as an officer certification regarding the accuracy of a previously filed semi-annual report. According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations, even if they reference a specific report type, should be classified as Regulatory Filings (RNS) rather than the report itself. H1 21
2025-08-05 Japanese
訂正有価証券届出書（参照方式）
Share Issue/Capital Change Classification · 95% confidence The document is a 'Yuka Shoken Todokesho' (Securities Registration Statement) filed with the Kanto Local Finance Bureau by SymBio Pharmaceuticals. It details the issuance of new share acquisition rights (stock options/warrants) to a third party (EVO FUND). This type of document is a formal regulatory filing required for capital raising activities in Japan. According to the provided filing categories, this fits best under 'Regulatory Filings' (RNS) as it is a formal disclosure document for securities issuance that does not fall into the specific categories like 'Share Issue/Capital Change' (which usually refers to the announcement of the change itself rather than the full registration statement) or 'Proxy Solicitation'.
2025-08-04 Japanese
半期報告書－第21期(2025/01/01－2025/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '半期報告書' (Semi-Annual Report) filed by SymBio Pharmaceuticals Limited in Japan. It covers the interim accounting period from January 1, 2025, to June 30, 2025. It contains detailed financial statements, management analysis (MDA), and corporate information, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2025
2025-08-04 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.